TITLE

Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area – model of the early beginning of Parkinson's symptomatology?

AUTHOR(S)
Heim, C.; Sova, L.; Kurz, T.; Kolasiewicz, W.; Schwegler, H.; Sontag, K.-H.
PUB. DATE
May 2002
SOURCE
Journal of Neural Transmission;May2002, Vol. 109 Issue 5/6, p691
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summary. To test substances which might have protective effects on the dopaminergic system it is necessary to use models with a pathological symptomatology of the early beginning, i.e. models in which the chance exists to arrest the otherwise progressive pathological processes (see Heim et al., 2001). 6-hydroxydopamine (6-OHDA) injected unilaterally into the ventrolateral striatum of rats (6 μg dissolved in 2 μl 0.2% ascorbic acid) leads to specific stereotyped movements after subcutaneous injection of apomor-phine both 3 and 13 weeks after surgery. Ten weeks after surgery decreased spontaneous motor activity could be observed. Twelve weeks after 6-hydroxydopamine injection, the animals had difficulties in performing a spatial navigation task when the submerged escape platform was moved to another position. The switching of motor programs was less pronounced. The application of tyrosine-hydroxylase-staining showed a loss of ipsilateral neurones of the substantia nigra compacta as well as of dendrites in the pars reticulata, neurones in the ventral tegmental area and in the retrorubral area ipsilaterally as well as a loss of dopaminergic fibres both ipsilaterally and contralaterally in the striatum which should belong to the contralateral acting substantia nigra afferents. The loss of the neurones and the afferents was induced by the retrograde denervation following the 6-OHDA injection within the ventrolateral striatum. The question arises whether the model used here with the partially loss of dopaminergic neurons and fibres reflects some of pathological symptoms of Parkinson's disease in the early states.
ACCESSION #
15397243

 

Related Articles

  • The neuromelanin of human substantia nigra and its interaction with metals. Zecca, L.; Tampellini, D.; Gatti, A.; Crippa, R.; Eisner, M.; Sulzer, D.; Ito, S.; Fariello, R.; Gallorini, M. // Journal of Neural Transmission;May2002, Vol. 109 Issue 5/6, p663 

    Summary. Neuromelanin (NM) is a peculiar biochemical component of several neurons in the Substantia Nigra (SN), the target area of the degenerative process in Parkinson Disease (PD). SN NM has peculiarities as to its composition and an impressive capacity of chelating metals, iron in particular,...

  • A channel to neurodegeneration. Deutch, Ariel Y.; Winder, Danny G. // Nature Medicine;Jan2006, Vol. 12 Issue 1, p17 

    The article determines the role of the differential vulnerability of dopamine cells in Parkinson disease. Neurons in certain brain regions of people suffering from the disease are more likely to die than others. Dysfunction of the mitochondrial electron transport chain increases in reactive...

  • Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Lindholm, Päivi; Voutilainen, Merja H.; Laurén, Juha; Peränen, Johan; Leppänen, Veli-Matti; Andressoo, Jaan-Olle; Lindahl, Maria; Janhunen, Sanna; Kalkkinen, Nisse; Timmusk, Tõnis; Tuominen, Raimo K.; Saarma, Mart // Nature;7/5/2007, Vol. 448 Issue 7149, p73 

    In Parkinson’s disease, brain dopamine neurons degenerate most prominently in the substantia nigra. Neurotrophic factors promote survival, differentiation and maintenance of neurons in developing and adult vertebrate nervous system. The most potent neurotrophic factor for dopamine neurons...

  • 3,4-Dihydroxyphenylacetaldehyde: A Potential Target for Neuroprotective Therapy in Parkinson's Disease. W.J. Burke // Current Drug Targets - CNS & Neurological Disorders;Apr2003, Vol. 2 Issue 2, p143 

    The simplest explanation for the selective loss of substantia nigra (SN) dopamine (DA) neurons in Parkinson''s disease (PD) is that DA or a metabolite is neurotoxic. Recently, a series of investigations implicate the MAO metabolite of DA, 3,4-dihydroxyphenylacetaldehyde (DOPAL), as the critical...

  • Endogenous Dopamine Is Involved in the Herbicide Paraquat-Induced Dopaminergic Cell Death. Izumi, Yasuhiko; Ezumi, Masayuki; Takada-Takatori, Yuki; Akaike, Akinori; Kume, Toshiaki // Toxicological Sciences;Jun2014, Vol. 139 Issue 2, p466 

    The herbicide paraquat is an environmental factor that may be involved in the etiology of Parkinson's disease (PD). Systemic exposure of mice to paraquat causes a selective loss of dopaminergic neurons in the substantia nigra pars compacta, although paraquat is not selectively incorporated in...

  • The Neurotoxicity of DOPAL: Behavioral and Stereological Evidence for Its Role in Parkinson Disease Pathogenesis. Panneton, W. Michael; Kumar, V. B.; Qi Gan; Burke, William J.; Galvin, James E. // PLoS ONE;2010, Vol. 5 Issue 12, p1 

    Background: The etiology of Parkinson disease (PD) has yet to be fully elucidated. We examined the consequences of injections of 3,4-dihydroxyphenylacetaldehyde (DOPAL), a toxic metabolite of dopamine, into the substantia nigra of rats on motor behavior and neuronal survival. Methods/Principal...

  • Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease. Mythri, R. B.; Bharath, M. M. Srinivas // Current Pharmaceutical Design;1/1/2012, Vol. 18 Issue 1, p91 

    Parkinson's disease (PD) is an age-associated neurodegenerative disease clinically characterized as a movement disorder. The motor symptoms in PD arise due to selective degeneration of dopaminergic neurons in the substantia nigra of the ventral midbrain thereby depleting the dopamine levels in...

  • Aged Tgfβ2/Gdnf double-heterozygous mice show no morphological and functional alterations in the nigrostriatal system. Heermann, Stephan; Opazo, Felipe; Falkenburger, Björn; Krieglstein, Kerstin; Spittau, Björn // Journal of Neural Transmission;Jun2010, Vol. 117 Issue 6, p719 

    Loss of dopaminergic neurons in the substantia nigra pars compacta and the resulting decrease in striatal dopamine levels are the hallmarks of Parkinson’s disease. Tgfβ and Gdnf have been identified as neurotrophic factors for dopaminergic midbrain neurons in vivo and in vitro....

  • GABAA receptor subunit expression in intrastriatal ventral mesencephalic transplants. Rodríguez-Pallares, Jannette; Caruncho, Héctor J.; Muñoz, Ana; José Guerra, María; Labandeira-García, José Luis // Experimental Brain Research;Dec2000, Vol. 135 Issue 3, p331 

    To compare the expression of GABAA receptor subunits in the normal substantia nigra and in fetal mesencephalic neurons ectopically transplanted into the dopamine-depleted striatum, we have employed single and double immunocytochemical approaches using tyrosine hydroxylase (TH) and α1, α2,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics